Overall and progression free survival in older patients receiving either auto-HCT or CAR-T therapy. OS (A) and PFS (B) in older patients aged ≥65 years with r/r DLBCL receiving auto-HCT or CAR-T therapy in PR (follow-up restricted to 24 months).